The International Journal of Romanian Society of Endocrinology / Registered in 1938

in ISI Thomson Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

July - September 2019, Volume 15, Issue 3
Case Series

Grigorie D, Sucaliuc A, Ciuffi S, Franceschelli F, Marini F, Ioachim D, Terzea D, Brandi ML

High Risk of Parathyroid Carcinoma and Genetic Screening in the First Diagnosed Romanian Family with Hyperparathyroidism-Jaw Tumor Syndrome and a Germline Mutation of the CDC73 Gene

Acta Endo (Buc) 2019, 15 (3): 398-403
doi: 10.4183/aeb.2019.398

Context. Hyperparathyroidism-jaw tumour (HPTJT) syndrome is a rare autosomal dominant cause of familial hyperparathyroidism associated with ossifying fibromas (OF) of the maxillofacial bones and increased risk of parathyroid carcinoma, caused by inactivating germline mutation of the cell division cycle 73 (CDC73) gene. Objective. To report the first Romanian family with HPT-JT and genetic screening of CDC73 gene. Subjects and Methods. Mutational analysis of the CDC73 gene and genetic screening of the family of a proband with HPT-JT. Histological diagnosis of parathyroid tumors (WHO criteria) and immunohistochemistry (parafibromin) were performed. Results. Three of the six screened family members had evidence of PHPT and surgically proven parathyroid tumours. Two of the three affected members had parathyroid carcinomas and one had two parathyroid adenomas. Genetic screening of CDC73 gene revealed that 4 of 6 patients showed a heterozygous germline deletion of one nucleotide: c.128-IVS1+1 delG. All the three affected patients, resulted to be carriers of the CDC73 mutation, but each one bearing a different CDC73 polymorphism. Conclusions. We identified a new CDC73 germline mutation in a Romanian family of HPT-JT. Analysis of clinical phenotypes in the four mutated individuals confirmed the incomplete penetrance and the variable clinical expression of the disease.

Keywords: Familial Primary Hyperparathyroidism, Parathyroid Carcinoma, HPT-JT, Germline CDC73 mutation, Genetic screening.

Correspondence: Daniel Grigorie MD, PhD, Associate Professor of Endocrinology, “Carol Davila” University of Medicine and Pharmacy, “C.I. Parhon” National Institute of Endocrinology, 34-38 Aviatorilor Blvd, Bucharest, 011863, Romania. E-mail: